Literature DB >> 29043374

[Overactive bladder-which treatment when?]

J Pannek1.   

Abstract

The term OAB (overactive bladder) describes a symptom complex. Therefore, initial treatment should be based on clinical symptoms and the results of basic diagnostics. Patient preference is essential for the choice of the initial treatment. Behavioural therapy, electrostimulation and medical treatment are available treatment options. If these are not effective, extended diagnostic examinations should be performed prior to minimally invasive treatments, like onabotulinumtoxin injections in the detrusor or sacral neuromodulation. Surgical interventions like augmentation cystoplasty are rarely required today.

Entities:  

Keywords:  Electrostimulation; Muscarin receptor antagonists; Nocturia; Onabotulinumtoxin; Sacral neuromodulation

Mesh:

Substances:

Year:  2017        PMID: 29043374     DOI: 10.1007/s00120-017-0522-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  35 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

Review 2.  Lower urinary tract symptomatology: Its definition and confusion.

Authors:  Yukio Homma
Journal:  Int J Urol       Date:  2008-01       Impact factor: 3.369

3.  Long-term follow-up of incontinence and urge complaints after intensive urotherapy in childhood (75 patients followed up for 16.2-21.8 years).

Authors:  Marianne A W Vijverberg; Eva Stortelder; Laetitia M O de Kort; Esther T Kok; Tom P V M de Jong
Journal:  Urology       Date:  2011-10-19       Impact factor: 2.649

4.  Overactive bladder inhibition in response to pelvic floor muscle exercises.

Authors:  Ahmed Shafik; Ismail A Shafik
Journal:  World J Urol       Date:  2003-04-04       Impact factor: 4.226

5.  Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.

Authors:  Hongde Chen; Feng Wang; Zhixian Yu; Yirong Zhang; Chaohui Liu; Shengjie Dai; Bicheng Chen; Jiaju Lv
Journal:  Urology       Date:  2016-11-11       Impact factor: 2.649

6.  Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.

Authors:  Nora Buser; Sandra Ivic; Thomas M Kessler; Alfons G H Kessels; Lucas M Bachmann
Journal:  Eur Urol       Date:  2012-09-07       Impact factor: 20.096

7.  [Neurogenic or idiopathic destrusor overactivity after failed antimuscarinic treatment : clinical value of external temporary electrostimulation].

Authors:  J Pannek; S Janek; J Noldus
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

8.  Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.

Authors:  Steven Siegel; Karen Noblett; Jeffrey Mangel; Tomas L Griebling; Suzette E Sutherland; Erin T Bird; Craig Comiter; Daniel Culkin; Jason Bennett; Samuel Zylstra; Fangyu Kan; Elizabeth Thiery
Journal:  Urology       Date:  2016-04-27       Impact factor: 2.649

9.  The Functional Effects of Cigarette Smoking in Women on the Lower Urinary Tract.

Authors:  Chendrimada Madhu; Doyo Enki; Marcus J Drake; Hashim Hashim
Journal:  Urol Int       Date:  2015-10-10       Impact factor: 2.089

10.  Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan.

Authors:  Chen-Li Cheng; Jian-Ri Li; Ching-Heng Lin; William C de Groat
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more
  1 in total

1.  Effect of preoperative gabapentin after transurethral prostate resection under general anesthesia. A randomized double-blind, placebo-controlled trial.

Authors:  Jinguo Wang; Guosheng Fu; Junyan Liu; Yunhai Yu; Na Wang
Journal:  Saudi Med J       Date:  2020-06       Impact factor: 1.484

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.